CANC Tema Oncology ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 45.31 | Day Range | 44.51 – 45.22 |
| 52-Week Range | 26.52 – 47.00 | Volume | 15.94K |
| Avg Volume | 30.36K | AUM | $218.5M (Aug 27, 2026) |
| Expense Ratio | 0.99% | Yield (TTM) | 0.04% |
| NAV | 45.14 | Premium/Discount | -0.65% indicative |
| Inception | Aug 14, 2023 | Holdings | 59 |
| Issuer | Tema | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 87975E701 | ISIN | US87975E7013 |
| Management | Not stated in source data | ||
About this ETF
The Tema Oncology ETF (CANC) is designed to strategically invest in companies well-positioned to capitalize on significant advancements within cancer-focused biotechnology and the broader healthcare sector.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +10.14% | +18.85% | +19.20% | +30.29% | +71.67% | +21.96% | — | — | +22.54% |
| Total return | +10.15% | +18.86% | +19.21% | +30.30% | +71.82% | +23.34% | — | — | +23.92% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.99% | Annual cost of a $10,000 investment | $99.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 59 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC | RVMD | 5.96% | 61.26K | $12.8M |
| 2 | ELI LILLY & CO | LLY | 5.44% | 9.33K | $11.7M |
| 3 | COGENT BIOSCIENCES INC | COGT | 4.79% | 281.12K | $10.3M |
| 4 | ROCHE HOLDING AG | RHHBY | 4.39% | 162.72K | $9.5M |
| 5 | NOVARTIS AG | NOVN.SW | 3.84% | 52.04K | $8.3M |
| 6 | MERCK & CO INC | MRK | 3.57% | 50.46K | $7.7M |
| 7 | BRISTOL-MYERS SQUIBB CO | BMY | 3.48% | 112.00K | $7.5M |
| 8 | ABBVIE INC | ABBV | 3.34% | 27.11K | $7.2M |
| 9 | BEONE MEDICINES LTD | ONC | 3.22% | 18.52K | $6.9M |
| 10 | HALOZYME THERAPEUTICS INC | HALO | 3.15% | 62.65K | $6.8M |
| 11 | JOHNSON & JOHNSON | JNJ | 3.06% | 24.36K | $6.6M |
| 12 | IMMUNOME INC | IMNM | 3.03% | 229.07K | $6.5M |
| 13 | CG ONCOLOGY INC | CGON | 2.85% | 76.92K | $6.1M |
| 14 | GENMAB A/S | GMAB | 2.82% | 181.86K | $6.1M |
| 15 | IDEAYA BIOSCIENCES INC | IDYA | 2.60% | 141.11K | $5.6M |
| 16 | EXELIXIS INC | EXEL | 2.53% | 100.63K | $5.4M |
| 17 | BRIDGEBIO PHARMA INC | BBIO | 2.41% | 63.74K | $5.2M |
| 18 | ENLIVEN THERAPEUTICS INC | ELVN | 2.05% | 73.87K | $4.4M |
| 19 | AMGEN INC | AMGN | 2.04% | 10.02K | $4.4M |
| 20 | ASTRAZENECA PLC | AZN.L | 2.00% | 25.77K | $4.3M |
| 21 | LEGEND BIOTECH CORP | LEGN | 1.99% | 196.31K | $4.3M |
| 22 | ZAI LAB LTD | ZLAB | 1.93% | 159.96K | $4.2M |
| 23 | CELCUITY INC | CELC | 1.85% | 42.49K | $4.0M |
| 24 | ERASCA INC | ERAS | 1.69% | 206.49K | $3.6M |
| 25 | RELAY THERAPEUTICS INC | RLAY | 1.66% | 183.63K | $3.6M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.04% | Paid (last 12 months) | $0.0196 |
| Frequency | Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 10, 2025 | Last payment | $0.0196 (Dec 11, 2025) |
| Growth 1Y | -97.31% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 10, 2025 | Dec 10, 2025 | Dec 11, 2025 | $0.0196 |
| Dec 11, 2024 | Dec 11, 2024 | Dec 12, 2024 | $0.7283 |
| Dec 13, 2023 | Dec 14, 2023 | Dec 15, 2023 | $0.1491 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 22.86% / 23.18% | Sharpe 1Y / 3Y | 3.19 / 0.999 |
| Max drawdown 1Y / 3Y | -9.29% / -28.04% | Sortino 1Y | 5.52 |
| Beta vs S&P 500 (3Y) | 0.774 | Correlation vs S&P 500 (1Y) | 0.388 |
| Downside deviation 1Y | 13.22% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 15.94K | Average volume | 30.36K |
| AUM | $218.5M | Premium/Discount | -0.65% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$1.1M | -0.52% | $215.4M → $214.2M |
| 1 Week | $6.9M | +3.34% | $207.1M → $214.2M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for CANC
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.